Valuation: Photonstar Led Group PLC

Market Cap 5.71T 4.96T 4.63T 4.25T 8.02T 5L 8.16T 54.6T 21.38T 3L 21.44T 20.96T 9L P/E 2019
-0.01x
P/E 2020 -0.02x
Enterprise Value -78.29T -68.04T -63.53T -58.32T -1L -74.63L -1L -7L -3L -37.21L -3L -3L -1.23Cr EV / Sales 2019
-
EV / Sales 2020 -
Free-Float
76.48%
Yield 2019 *
-
Yield 2020 -
Manager TitleAgeSince
Director of Finance/CFO 65 14/05/2021
Chief Tech/Sci/R&D Officer 61 02/01/2025
Director TitleAgeSince
Director/Board Member 45 29/01/2019
Chairman 70 21/05/2019
Director/Board Member 61 14/05/2021
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-99.07% - - 35.44L
+1.86%-0.44%+9.73%+101.26% 994.62Cr
-1.72%-9.95%+264.67% - 233.96Cr
+1.63%+6.01%-28.02%-46.04% 205.07Cr
+2.36%+4.16%-4.62%-13.70% 194.63Cr
+1.00%+4.11%-21.15%-10.74% 100.39Cr
+3.12%+3.74%+34.07%+93.27% 86Cr
-0.57%0.00%+51.74%+12.58% 73Cr
+4.00%+0.90%+30.52%+71.48% 58Cr
+1.15%+1.92%-8.93%+4.13% 56Cr
Average +1.28%+2.61%+36.45%+26.53% 222.47Cr
Weighted average by Cap. +1.43%+1.21%+35.37%+57.03%

Financials

2019 2020
Net sales - -
Net income -8L -7L -7L -6L -11.69L -7.93Cr -11.89L -79.6L -31.18L -3.95Cr -31.25L -30.56L -13Cr -3L -3L -2L -2L -4L -2.92Cr -4L -29.28L -11.47L -1.45Cr -11.49L -11.24L -4.8Cr
Net Debt -4L -3L -3L -3L -5L -3.6Cr -5L -36.17L -14.16L -1.8Cr -14.2L -13.88L -5.93Cr -84T -73T -68.16T -62.57T -1L -80.07L -1L -8L -3L -39.93L -3L -3L -1.32Cr
Logo Photonstar Led Group PLC
Cizzle Biotechnology Holdings PLC is a United Kingdom-based diagnostics developer of early cancer tests. The Company is focused on early detection of lung cancer via the development of an immunoassay test for the CIZ1B biomarker. CIZ1B is a variant of CIZ1, a naturally occurring cell nuclear protein involved in protecting deoxyribonucleic acid (DNA). Its CIZ1B biomarker detects lung cancer at its earliest and most treatable stage. It is designed as a simple blood test, which enables early diagnosis before symptoms appear-when treatment options can transform outcomes for patients and families.
Employees
-